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Background. Although familial susceptibility to glioma is known, the genetic basis for this susceptibility remains unidentified in the
majority of glioma-specific families. An alternative approach to identifying such genes is to examine cancer pedigrees, which include
glioma as one of several cancer phenotypes, to determine whether common chromosomal modifications might account for the fa-
milial aggregation of glioma and other cancers.
Methods. Germline rearrangements in 146 glioma families (from the Gliogene Consortium; http://www.gliogene.org/) were examined
using multiplex ligation-dependent probe amplification. These families all had at least 2 verified glioma cases and a third reported or
verified glioma case in the same family or 2 glioma cases in the family with at least one family member affected with melanoma,
colon, or breast cancer.The genomic areas covering TP53, CDKN2A, MLH1, and MSH2 were selected because these genes have been
previously reported to be associated with cancer pedigrees known to include glioma.
Results. We detected a single structural rearrangement, a deletion of exons 1-6 in MSH2, in the proband of one family with 3 cases
with glioma and one relative with colon cancer.
Conclusions. Large deletions and duplications are rare events in familial glioma cases, even in families with a strong family history of
cancers that may be involved in known cancer syndromes.
Keywords: CDKN2A/B, family history, glioma, MLH1, MSH2, TP53.
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Diffuse gliomas are the most common group of primary malig-
nant brain tumors.1 Family history is an important risk factor for
glioma, with first-degree relatives of glioma patients having an
increased risk of developing the disease.2–4 Although a small per-
centage of these families with glioma are attributed to hereditary
genetic disorders such as neurofibromatosis types I and II,
Li-Fraumeni syndrome, and Turcot’s syndrome,5,6 the genes
underlying the appearance of multiple gliomas in most families
remain ill defined. In addition to the familial aggregation of
glioma-specific risk, the risk of other cancers in first-degree rela-
tives of glioma patients has been noted, and significantly more
melanoma cases than expected have been identified.7 High-
penetrance genes such as the tumor suppressor gene TP53
have been described in families with Li-Fraumeni syndrome;
these families include persons diagnosed with glioma as well as
other malignancies such as breast cancer, sarcoma, and leuke-
mia. Moreover, these genes have also been associated with gli-
oma and low-penetrant genetic variants in the CDKN2A
(p16INK4A/p14ARF) and TP53 genomic area.8–11
Gliomas have been observed in families with mutations in the
CDKN2A and TP53 genes, but most of the studies published to
date are based on small sample sizes with limited power to as-
sess the contribution ofmutations in these genes with familial gli-
oma.12 –17 In an earlier study, we used standard sequencing,
which was ineffective in detecting large rearrangements of
TP53 and CDKN2A in 96 unselected glioma families. Only one pro-
band had a TP53 mutation, and no functional mutations were
found in CDKN2A.18
The association between glioma andmelanoma has been pre-
viously reported in aggregation studies3,19–21 and is supported by
linkage of melanoma to regions of chromosome 9,22,23which has
been reported to be deleted or mutated in glioma.24–26 Further-
more, recent genome-wide association studies of both glioma9,10
and melanoma27 have identified variants in chromosome 9p21
near the cyclin-dependent kinase inhibitor genes, CDKN2A,
CDKN2B, and other genes. Although the variants identified for gli-
oma andmelanoma are not in the same linkage block, the results
indicate the plausibility that deletions or other chromosomal
modifications in the region might account for some familial ag-
gregation of glioma and melanoma. The melanoma-neural sys-
tem tumor syndrome, in which affected families have increased
risk of melanoma and astrocytoma, was recently linked to loss of
the CDKN2A/B genes located on chromosome 9.
The mismatch repair (MMR) genes, MLH1, MSH2, MSH6, and
PMS2, play a basic role in maintaining genome integrity by cor-
recting single-base pair mismatches after DNA replication.28 It
is well established that the etiological basis for Lynch syndrome
is heterozygous germline mutations within one of the mismatch
genes, MLH1, MSH2, MSH6 and PMS2, with MLH1 and MSH2muta-
tions playing a major role.29 Lynch syndrome patients are suscep-
tible to colorectal, endometrial, and other cancers recognized by
microsatellite instability (MSI), which is a hallmark of MMR
defects.30 –32 Lynch syndrome is associated with an increased
risk of brain tumors.33–In carriers of pathogenic MLH1 or MSH2
mutations or their first-degree relatives, the cumulative risk of
brain tumors to the age of 70 years was 1.7% for carriers of
MLH1 mutations and 2.5% for carriers of MSH2 mutations.36
Mean age (38 years) at the time of brain tumor diagnosis is
lower in those with Lynch syndrome than in the general popula-
tion, and the most common tumor types are glioblastoma and
astrocytoma.37 Biallelic mutations in MSH2 have been shown to
be associated with childhood brain tumors.38 A heterozygous
germline mutation in MSH2 is also known to be involved in
patients with a syndrome diagnosis (eg, Turcot’s syndrome),
in which some patients have an inherited predisposition for
brain tumors and colorectal cancer.39 The results listed above
suggest the possibility that deletions or other chromosomal mod-
ifications in common chromosomal regions might account for
some familial aggregation of glioma and other cancers, notably
melanoma, colon, and breast cancer.
Materials and Methods
Ascertainment and Collection of Families
All families were identified through the Gliogene Consortium, and
the exclusions were based on reported information obtained from
the questionnaire in which we asked about the clinical criteria
used for these hereditary conditions. We excluded all families
with a reported or confirmed diagnosis of neurofibromatosis I,
neurofibromatosis II, Turcot’s syndrome, or tuberous sclerosis.
The recruitment protocol and data collection procedures for this
study have been previously described.40 We identified 146 (34%)
families meeting the criteria of having both familial glioma and
associated cancers out of 428 probands recruited from 14 569
screened cases of incident glioma cases. The cases were initially
screened for family history of glioma and had been diagnosed be-
tween 2007 and 2011 at one of our 14 recruitment centers. DNA
was extracted from EDTA-venous blood samples and/or saliva
samples. Biospecimen and clinicopathological information from
probands and the above description of selected family members
were collected after obtaining informed consent according to pro-
tocols approved by each center’s institutional review board in ac-
cordance with the Declaration of Helsinki. The genomic areas
covering TP53, CDKN2A, MLH1, and MSH2 were selected because
these genes have previously been reported to be associated with
cancer pedigrees known to include glioma. Families with 2 or
more verified gliomas were recruited between 2007 and 2011.
Distributions of demographic characteristics of the probands,
pathological characteristics of the glial tumors, and clinical vari-
ables of glioma in the families were described based on informa-
tion derived from personal questionnaires40,41 (Table 1). Glioma
families were included from Sweden (n¼ 14), Denmark (n¼ 36),
Israel (n¼ 10), and the United States (n¼ 86) (Table 2). The first
category was families with at least 2 glioma cases verified and a
third reported or verified in the same family (n¼ 67: Sweden n¼
7, Denmark n¼ 12, Israel n¼ 5, United States n¼ 43). (Inter-
national Classification of Diseases codes for oncology: low
grade glioma [WHO grades I and II]: juvenile pilocytic astrocy-
toma [9421/3], fibrillary astrocytoma [9420/3], protoplasmic
astrocytoma [9410/3], gemistocytic astrocytoma [9411/3], dif-
fuse astrocytoma [9400/3], oligodendroglioma [9450/3], oligoas-
trocytoma [9382/3], ependymoma [9391/3]; high-grade glioma
[WHO grades III and IV]: anaplastic astrocytoma [9401/3], ana-
plastic oligodendroglioma [9451/3], anaplastic oligoastrocytoma
[9382/3], anaplastic ependymoma [9392/3], gliosarcoma [9442/
3], gliomatosis cerebri [9381/3], and glioblastoma [9440/3]). The
second category was families with ≥ 2 glioma cases plus a report
of at least one family member affected with colon cancer, breast
cancer, or malignant melanoma (n¼ 128: Sweden n¼ 12,
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Denmark n¼ 38, Israel n¼ 8, and United States n¼ 70). Some
families belonged to both categories, having ≥ 3 cases of glioma,
and another cancer in the family (n¼ 37: Sweden n¼ 5, Denmark
n¼ 9, Israel n¼ 3, and United States n¼ 20) (Table 2).
Multiplex Ligation-dependent Probe Amplification
MLH1 and MSH2
The samples were screened for large deletions/duplications by
multiplex ligation-dependent probe amplification (MLPA). MLPA
is a method for copy number detection by the multiplex PCR
method. Small (50–70 nt) sequences are targeted, enabling
MLPA to identify single exon aberrations. The samples were
ligated and amplified using the SALSA MLPA P003 MLH1/MSH2
probe mix version B2 according to the protocol manufacturer’s
recommendation (MRC-Holland). The P003 MLH1/MSH2 probe
mix version 2 contains probes for each of the 19 exons of the
MLH1 gene and for each of the 16 exons of the MSH2 gene.
Also, 2 probes are included for the most 3′ exon of EPCAM, a
gene located just upstream of the MSH2 gene. Deletions of the
most 3′ exon of the EPCAM gene can result in silencing of the
MSH2 gene. In addition, the P003MLH1/MSH2 probe mix also cov-
ers 7 genes in the CDKN2A-9p21 region+ PAX5 (9p13) DOCK8
(9p24.3), and GLDC (9p21.1). The samples were analyzed on a
CEQTM 8000 GeneticAnalysis System (Beckman Coulter Inc.).
Data normalization and analysis were performed with GeneMarker
Software version 1.75 (SoftGenetics) using standard parameters.
TP53 and CDKN2A/B
Standard MLPA analysis was performed following the manufac-
turer’s instructions (MRC-Holland), version 31; 17-06-211. One
hundred nanograms of genomic DNA were denatured and then
hybridized with SALSA MLPA probe mixes that covers 6 genes in
the TP53-17p13.1 region+NF2 and CHEK2 (included CHEK2*1100-
delC). Probe mixes used were P056-A2 for TP53 and ME024-B1
9p21 for CDKN2A/2B. Following ligation, PCR was performed in a
Bio-Rad 1000series Thermal Cycler (Bio-Rad Laboratories). Frag-
ment separation was carried out as suggested by MRC-Holland
on an ABI 3100 sequencer using POP7 polymer and GeneScan-
500 ROX sizing standard (Applied Biosystems). 8.75 mL of Hi-Di For-
mamide and 0.25 mL of GeneScan-500 ROX sizing standard were
mixed with 1 mL of the MLPA PCR product per sample for a total
volume of 10 mL. Data were analyzed with the SoftGenetics Gene-
Marker software version 1.6 from SoftGenetics LLC.
Next-generation Sequencing
Since some of the variants found in this study were not standar-
dized and clinically validated mutations, we used massively par-
allel sequencing of hybrid-captured DNA to further evaluate
preliminary findings from MLPA screening of genes in the 9p21 re-
gion. Agilent SureSelect probes were designed to capture the gen-
omic regions of CDKN2A and CDKN2B, including introns and 20 kb
adjacent 5′ and 3′ regions, which covered the regions implicated
by MLPA. Paired-end sequencing 2×100 bp was performed on
Table 1. Demographic characteristics of the probands and pathological characteristics of the glial tumors from Sweden, Denmark, Israel, and United
States ascertained for multiplex ligation-dependent probe amplification analyses of TP53, CDKN2A/B, MLH1 and MSH2
Glial Tumor (pathological characteristics) Number of Affected
Individuals
Median Age
at Diagnosis (y)a
Sex Race
Male/Female White/Black/Hispanic/Arabic
Astrocytic tumors
Astrocytoma, unclassified 3 43.0 2/1 2/0/1/0
Astrocytoma, fibrillary 1 43.0 0/1 1/0/0/0
Astrocytoma, gemistocytic 1 31.0 0/1 1/0/0/0
Astrocytoma, juvenile pilocytic 1 2.0 0/1 1/0/0/0
Astrocytoma, diffuse 9 29.0 3/6 8/0/1/0
Astrocytoma, anaplastic 18 47.0 11/7 18/0/0/0
Ganglioglioma 2 29.0 0/2 2/0/0/0
Glioma, unclassified 5 39.0 2/3 5/0/0/0
Glioblastoma 64 56.0 35/29 61/2/0/1
Oligodendroglial tumors
Oligodendroglioma 17 42.0 9/8 16/0/1/0
Oligodendroglioma, anaplastic 10 51.5 2/8 10/0/0/0
Oligoastrocytoma 3 34.0 1/2 3/0/0/0
Oligoastrocytoma, anaplastic 3 45.0 1/2 3/0/0/0
Eppendymal tumors
Ependymoma, myxopapillary 2 24.5 0/2 2/0/0/0
Ependymoma 3 28.0 0/3 3/0/0/0
Ependymoma, anaplastic 1 60.0 0/1 1/0/0/0
Neuronal and mixed neuronal-glial tumors
Dysembryoplastic neuroepithelial tumor 1 28.0 0/1 1/0/0/0
Paraganglioma of spinal cord 1 51.0 0/1 1/0/0/0
aMedian age at diagnosis of probands.
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the Illumina HiSeq2000 instrument to an average depth of.100
reads, followed by alignment to the reference genome. Coverage
over the suspected deleted/duplicated regions was not found to
be different from coverage in control samples.
Results
Wewere able to successfully analyze 127 out of 146 glioma cases
for TP53 and CDKN2A/B. One hundred thirty-seven out of 146 gli-
oma cases were also successfully analyzed for MLH1 and MSH2.
One mutation found was a deletion of exon 1-6 inMSH2; this mu-
tation was present in the proband of a single family. The family
included 3 glioma cases and 1 relative with colon cancer
(Table 3). The proband in this family was diagnosed with anaplas-
tic oligodendroglioma at age 63 years. The other affected rela-
tives in this family were a maternal first cousin diagnosed with
anaplastic astrocytoma at age 32 years, a maternal first cousin’s
child diagnosed with oligodendroglioma at age 51 years, and a
maternal aunt diagnosed with colon cancer at age 84 years
(Table 3). Another aberration found was the variant CHEK2
1100delC, and this aberration was present in one family that
included 3 cases with glioma and one relative with breast cancer
(Table 3). The proband in this family was diagnosed with an oligo-
dendroglioma at age 70 years. The other affected relatives were
the proband’s mother, whowas diagnosed with a glioblastoma at
age 72 years, the child of themother’s first cousin diagnosed with
a glioblastoma at age 41 years, and a maternal aunt diagnosed
with breast cancer at age 38 years.
In addition, we found, a duplication at the promoter of
CDKN2Aprom dupl1022before ex1 (in 3 of the families), a deletion
at exon 2 of EFNB3 delex2 (in 2 of the families) and a duplication
of GLDC dupl9p24.1 (in one family) but these aberrations could
not be verified by next-generation sequencing (Table 2).
Discussion
In this large family study of gliomas, we found one large deletion
in exons 1-6 of MSH2 in one of the Swedish families with a family
history of colon cancer. This mutation was originally detected in 9
apparently unrelated multigenerational kindred with Lynch syn-
drome. The sequence of the breakpoints of the exon 1-6 deletions
and the haplotypes surrounding the mutation were identical in all
9 kindred, suggesting a common origin of the mutation.42 A simi-
lar mutation was reported as an American Founder Mutation in
Table 2. Descriptive characteristics of glioma families from Sweden, Denmark, Israel, and United States ascertained for multiplex ligation-dependent
probe amplification analyses of TP53, CDKN2A/B, MLH1 and MSH2
Categories Number of Affected
Individualsb
Median Age
at Diagnosisa
Non-GBM GBM
n (%) n (%)
Pedigrees available for MLPA analysis
United States 85 45.0 49 (57.0) 36 (43.0)
Sweden 14 57.0 8 (57.1) 6 (42.9)
Denmark 36 51.0 18 (50.0) 18 (50.0)
Israel 10 49.5 5 (50.0) 5 (50.0)
Pedigrees with ≥3 glioma
United States 43 48.0 20 (46.5) 23 (53.5)
Sweden 7 60.0 6 (85.7) 1 (14.3)
Denmark 11 56.0 5 (45.5) 6 (54.5)
Israel 5 56.0 1 (20.0) 4 (80.0)
Pedigrees with ≥2 glioma+ colon cancer
United States 53 45.0 19 (35.2) 34 (64.8)
Sweden 10 52.0 4 (40.0) 6 (60.0)
Denmark 25 50.0 10 (40.0) 15 (60.0)
Israel 1 35.0 1 (100.0) NA
Pedigrees with ≥2 glioma+ breast cancer
US 35 48.0 15 (42.9) 20 (57.1)
Sweden 5 60.0 3 (60.0) 2 (40.0)
Denmark 24 45.0 12 (50.0) 12 (50.0)
Israel 8 41.0 5 (62.5) 3 (37.5)
Pedigrees with ≥2 glioma+malignant melanoma
United States 16 51.5 10 (62.5) 6 (37.5)
Sweden 0 NA NA NA
Denmark 9 61.0 5 (55.6) 4 (44.4)
Israel 2 41.0 2 (100.0) NA
aMedian age at diagnosis of probands.
bOverlap because some of the probands were included in several categories.
Abbreviations: MLPA, multiplex ligation-dependent probe amplification; N, number of affected individuals; NA, not applicable.
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families with Lynch syndrome, an autosomal-dominant cancer
syndrome traced back to a single couple who migrated from Ger-
many, and settled in Pennsylvania in the early 1700s. Lynch syn-
drome is known to be associated with hereditary colorectal
cancer43,44 and several extracolonic cancers including endomet-
rial, gastric, small-bowel, renal, ovarian, and brain.33,36 Despite a
low incidence, brain tumors were the third highest cancer-related
cause of death in a large Dutch cohort of patients with Lynch syn-
drome.45 Germline mutations in MSH2 have also been described
in families with a syndrome diagnosis such as Turcot’s syndrome,
which is clinically characterized by occurrence of primary brain
tumors and colorectal cancer.39 Mutations in MSH2 result in pro-
duction of a faulty, truncated, or absent protein, which impairs
the ability of the MMR system to recognize and repair DNA mis-
matches.46 We also identified rearrangements in the promoter
of CHEK2, the variant CHEK2 1100delC, in one American family
having a family history of breast cancer. CHEK2 acts as a check-
point gene, activated in response to DNA damage, and encodes a
serine/threonine-protein kinase that phosphorylates P53. The
germline 1100delC variant of CHEK2 is a frameshift mutation,
resulting in a truncated and nonfunctional protein.47 Neverthe-
less, CHEK2 is a well-known median penetrant gene that is
quite common in the population. Published data suggest that
CHEK2 is not involved in familial glioma.48,49
In addition, a novel duplication was identified in the promoter
region of CDKN2A. To our knowledge, this specific aberration in the
promoter has not been previously described in the literature. The
aberration in CDKN2Awas present in 3 families, all of which have a
family history of both breast and colon cancer. Unfortunately, we
were unable to confirm this aberration by additional deep-
sequencing methods. Because of the unusual structure of
CDKN2A, mutations in this locus may affect both p16INK4a and
p14ARF depending on the localization and type of sequence alter-
ation. The p16INK4a has been found to be inactivated in the vast
majority of melanomas through mutation, deletion, or promoter
hypermethylation of CDKN2A.50 The CDKN2A has, as a low pene-
trant risk loci, been associated with risk of glioma and melanoma
in genome-wide association studies. The aberration discovered
in CDKN2A supports the finding that germline mutations in
CDKN2A/CDKN2B could cause the co-occurrence of the
melanoma-astrocytoma syndrome reported previously.51 –53
However, we did not observe the CDKN2A aberration in our fam-
ilies with a family history of melanoma, so it might be possible
that other low-penetrance genes contributed to the melanoma-
astrocytoma syndrome in this study.
In conclusion, candidate genes in known syndromes do not
explain these glioma-prone families. Large rearrangements are
uncommon events explaining cancer-prone glioma families,
and novel strategies of exome and whole genome sequencing
of glioma families with similar phenotypes are one likely strategy
for the future.
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